Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BSEM BioStem Technologies	$13.50 +0.9%	$13.14	$6.95 ▼ $28.26	$225.45M	-0.31	49,370 shs	53,424 shs
NRIX Nurix Therapeutics	$11.64 -1.7%	$11.03	$8.18 ▼ $29.56	$887.43M	2.16	835,196 shs	2.06 million shs
PRAX Praxis Precision Medicines	$43.00 -2.4%	$39.77	$26.70 ▼ $91.83	$875.91M	2.61	365,748 shs	607,522 shs
RCUS Arcus Biosciences	$7.94 -6.5%	$8.80	$6.50 ▼ $18.98	$841.19M	0.83	872,276 shs	3.75 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BSEM BioStem Technologies	0.00%	-1.74%	+22.00%	+56.98%	+51.69%
NRIX Nurix Therapeutics	0.00%	+1.31%	+9.60%	-2.02%	-44.23%
PRAX Praxis Precision Medicines	0.00%	+1.56%	+11.46%	+13.55%	+3.97%
RCUS Arcus Biosciences	0.00%	-8.32%	-11.54%	+0.99%	-47.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BSEM BioStem Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	1.1718 of 5 stars	3.4	0.0	0.0	0.0	2.0	0.8	0.0
PRAX Praxis Precision Medicines	3.2258 of 5 stars	4.4	2.0	0.0	0.0	3.7	1.7	0.0
RCUS Arcus Biosciences	3.0217 of 5 stars	4.4	3.0	0.0	0.0	1.8	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BSEM BioStem Technologies	0.00	N/A	N/A	N/A
NRIX Nurix Therapeutics	2.83	Moderate Buy	$30.18	159.25% Upside
PRAX Praxis Precision Medicines	2.80	Moderate Buy	$109.90	155.58% Upside
RCUS Arcus Biosciences	2.89	Moderate Buy	$21.29	167.95% Upside

Current Analyst Ratings Breakdown

Latest BSEM, RCUS, NRIX, and PRAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
6/2/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	$97.00
5/9/2025	RCUS Arcus Biosciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $22.00
5/8/2025	RCUS Arcus Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$15.00 ➝ $13.00
5/7/2025	PRAX Praxis Precision Medicines	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
5/7/2025	RCUS Arcus Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$33.00
5/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$29.00 ➝ $26.00
5/5/2025	PRAX Praxis Precision Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$26.00 ➝ $28.00
5/5/2025	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/1/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00 ➝ $105.00
4/29/2025	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BSEM BioStem Technologies	$301.83M	0.75	N/A	N/A	N/A	∞
NRIX Nurix Therapeutics	$54.55M	16.27	N/A	N/A	$7.44 per share	1.56
PRAX Praxis Precision Medicines	$8.55M	102.45	N/A	N/A	$23.90 per share	1.80
RCUS Arcus Biosciences	$258M	3.26	N/A	N/A	$5.30 per share	1.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BSEM BioStem Technologies	N/A	$1.47	9.18	5.90	N/A	N/A	N/A	N/A	8/11/2025 (Estimated)
NRIX Nurix Therapeutics	-$193.57M	-$2.80	N/A	N/A	N/A	-369.40%	-47.49%	-36.10%	7/10/2025 (Estimated)
PRAX Praxis Precision Medicines	-$182.82M	-$10.72	N/A	N/A	N/A	-2,137.48%	-50.42%	-46.74%	8/12/2025 (Estimated)
RCUS Arcus Biosciences	-$283M	-$4.19	N/A	N/A	N/A	-258.94%	-70.58%	-32.97%	8/4/2025 (Estimated)

Latest BSEM, RCUS, NRIX, and PRAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/10/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.73	N/A	N/A	N/A	$16.26 million	N/A
5/12/2025	Q4 2024	BSEM BioStem Technologies	$1.25	$0.17	-$1.08	$0.17	$101.20 million	$72.53 million
5/6/2025	Q1 2025	RCUS Arcus Biosciences	-$1.02	-$1.14	-$0.12	-$1.14	$38.61 million	$28.00 million
5/2/2025	Q1 2025	PRAX Praxis Precision Medicines	-$3.20	-$3.29	-$0.09	-$3.29	$0.20 million	N/A
4/8/2025	Q1 2025	NRIX Nurix Therapeutics	-$0.72	-$0.67	+$0.05	-$0.67	$12.78 million	$18.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BSEM BioStem Technologies	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BSEM BioStem Technologies	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	6.26	6.26
PRAX Praxis Precision Medicines	N/A	8.44	8.44
RCUS Arcus Biosciences	0.09	5.37	5.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BSEM BioStem Technologies	N/A
NRIX Nurix Therapeutics	N/A
PRAX Praxis Precision Medicines	67.84%
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
BSEM BioStem Technologies	N/A
NRIX Nurix Therapeutics	7.40%
PRAX Praxis Precision Medicines	2.70%
RCUS Arcus Biosciences	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BSEM BioStem Technologies	N/A	16.70 million	N/A	N/A
NRIX Nurix Therapeutics	300	76.24 million	70.60 million	Optionable
PRAX Praxis Precision Medicines	110	20.37 million	19.82 million	Optionable
RCUS Arcus Biosciences	500	105.89 million	95.72 million	Optionable

BSEM, RCUS, NRIX, and PRAX Headlines

Recent News About These Companies

Arcus Biosciences (NYSE:RCUS) Trading Down 6.3% - Here's What Happened

June 27 at 4:36 PM | marketbeat.com

Incyte, FDA, Sun Pharma and more—Chutes & Ladders

June 27 at 3:58 PM | fiercebiotech.comF

Arcus Biosciences Announces New Employment Inducement Grants - Business Wire

June 26, 2025 | businesswire.com

Precision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’

June 26, 2025 | msn.com

Brokerages Set Arcus Biosciences, Inc. (NYSE:RCUS) Target Price at $24.13

June 26, 2025 | americanbankingnews.com

Precision BioSciences Shares Surge Following FDA Rare Pediatric Disease Designation

June 25, 2025 | msn.com

Precision BioSciences gets FDA rare disease status for DMD treatment, stock jumps 10%

June 25, 2025 | msn.com

Arcus Biosciences, Inc. (RCUS) Cash Flow - Yahoo Finance

June 24, 2025 | finance.yahoo.com

RCUS Arcus Biosciences, Inc. - Seeking Alpha

June 24, 2025 | seekingalpha.com

Arcus Biosciences Announces New Employment Inducement Grants

June 24, 2025 | businesswire.com

Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of "Moderate Buy" by Analysts

June 23, 2025 | marketbeat.com

The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble

June 13, 2025 | fiercebiotech.comF

Arcus Biosciences (NYSE:RCUS) Shares Down 3.8% - What's Next?

June 11, 2025 | marketbeat.com

Stock Traders Purchase Large Volume of Call Options on Arcus Biosciences (NYSE:RCUS)

June 11, 2025 | marketbeat.com

Arcus Biosciences Announces New Employment Inducement Grants

June 10, 2025 | businesswire.com

Research Analysts Offer Predictions for RCUS FY2026 Earnings

June 10, 2025 | marketbeat.com

H.C. Wainwright maintains Buy rating for Arcus Biosciences stock

June 4, 2025 | investing.com

Arcus Biosciences, Inc. (NYSE:RCUS) Short Interest Up 25.2% in May

June 4, 2025 | marketbeat.com

Arcus Biosciences (NYSE:RCUS) Trading 10.6% Higher - Here's What Happened

June 4, 2025 | marketbeat.com

Nuveen Asset Management LLC Has $1.96 Million Position in Arcus Biosciences, Inc. (NYSE:RCUS)

June 4, 2025 | marketbeat.com

Arcus Kidney Cancer Drug Casdatifan Advances to Challenge Merck’s Welireg

June 2, 2025 | biospace.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

BSEM, RCUS, NRIX, and PRAX Company Descriptions

BioStem Technologies OTCMKTS:BSEM

$13.50 +0.13 (+0.93%)

As of 06/27/2025 03:59 PM Eastern

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.

Nurix Therapeutics NASDAQ:NRIX

$11.64 -0.20 (-1.69%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$11.81 +0.17 (+1.46%)

As of 04:00 AM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Praxis Precision Medicines NASDAQ:PRAX

$43.00 -1.04 (-2.36%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$43.04 +0.03 (+0.08%)

As of 04:00 AM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Arcus Biosciences NYSE:RCUS

$7.94 -0.56 (-6.54%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$14.00 +6.06 (+76.23%)

As of 04:00 AM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time